HRP940545B1 - Vaccine against lyme disease - Google Patents

Vaccine against lyme disease

Info

Publication number
HRP940545B1
HRP940545B1 HR940545A HRP940545A HRP940545B1 HR P940545 B1 HRP940545 B1 HR P940545B1 HR 940545 A HR940545 A HR 940545A HR P940545 A HRP940545 A HR P940545A HR P940545 B1 HRP940545 B1 HR P940545B1
Authority
HR
Croatia
Prior art keywords
lyme disease
vaccine against
against lyme
antigen
auxiliaries
Prior art date
Application number
HR940545A
Other languages
English (en)
Inventor
M Markus Simon
E Ulrich Schaible
Klaus Eichmann
Michael Kramer
Wallich Reinhard
Original Assignee
Max Planck Gesellschaft
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25885304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP940545(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft, Deutsches Krebsforsch filed Critical Max Planck Gesellschaft
Publication of HRP940545A2 publication Critical patent/HRP940545A2/hr
Publication of HRP940545B1 publication Critical patent/HRP940545B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR940545A 1989-09-19 1994-09-15 Vaccine against lyme disease HRP940545B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3931236 1989-09-19
DE4015911A DE4015911A1 (de) 1989-09-19 1990-05-17 Impfstoff gegen die lyme-krankheit
YU177390A YU48250B (sh) 1989-09-19 1990-09-18 Postupak za pripremanje aktivne vakcine protiv lajmske bolesti

Publications (2)

Publication Number Publication Date
HRP940545A2 HRP940545A2 (en) 1997-04-30
HRP940545B1 true HRP940545B1 (en) 2000-06-30

Family

ID=25885304

Family Applications (1)

Application Number Title Priority Date Filing Date
HR940545A HRP940545B1 (en) 1989-09-19 1994-09-15 Vaccine against lyme disease

Country Status (24)

Country Link
US (6) US5178859A (fr)
EP (5) EP0643974B1 (fr)
JP (3) JP3205932B2 (fr)
KR (2) KR100205462B1 (fr)
AT (4) ATE191499T1 (fr)
AU (1) AU651560B2 (fr)
CA (1) CA2025597C (fr)
CZ (2) CZ284538B6 (fr)
DE (5) DE4015911A1 (fr)
DK (4) DK0418827T3 (fr)
ES (4) ES2082812T3 (fr)
FI (1) FI102248B1 (fr)
GR (3) GR3018995T3 (fr)
HK (2) HK1002405A1 (fr)
HR (1) HRP940545B1 (fr)
HU (2) HU212716B (fr)
IE (1) IE903377A1 (fr)
NO (2) NO311767B1 (fr)
NZ (1) NZ235260A (fr)
PL (2) PL170229B1 (fr)
PT (1) PT95349B (fr)
SI (1) SI9011773B (fr)
SK (3) SK283089B6 (fr)
YU (2) YU48250B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) * 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
SG47447A1 (en) 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ATE196425T1 (de) * 1990-07-06 2000-10-15 American Home Prod Impfstoff gegen die lyme-krankheit
CA2057536C (fr) * 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
EP0877085A1 (fr) * 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. Protéines OspA des sous-groupes borrelia burgdorferi, gènes codants et vaccins
WO1993008299A1 (fr) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation de proteines borrelia recombinees
EP0540457A1 (fr) * 1991-10-22 1993-05-05 Symbicom Ab Améliorations dans le diagnostic et dans le prophylaxie de Borrelia burgdorferi
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
US6437116B1 (en) 1996-02-21 2002-08-20 Board Of Regents, The University Of Texas System VMP-like sequences of pathogenic borrelia
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6458555B1 (en) * 1996-08-21 2002-10-01 Gerd Bach Cytologic method of examining mucous membranes
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6306623B1 (en) * 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32
WO2000006745A1 (fr) 1998-07-31 2000-02-10 Gundersen Lutheran Medical Foundation, Inc. UTILISATIONS, EN TANT QUE VACCIN, D'EPITOPE(S) BORRELIACIDAL DE PROTEINE C DE SURFACE EXTERIEURE (OSPC) DE $i(BORRELIA BURGDORFERI)
WO2000056298A2 (fr) * 1999-03-19 2000-09-28 Luitpold Pharmaceuticals, Inc. Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates
WO2000078345A1 (fr) * 1999-06-21 2000-12-28 Milkhaus Laboratory, Inc. Methode de traitement de la maladie de lyme
ES2298249T3 (es) 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
US7847084B2 (en) 2002-12-20 2010-12-07 Board Of Regents, The University Of Texas System VMP-like sequences of pathogenic Borrelia species and strains
SG176451A1 (en) 2006-11-03 2011-12-29 Schering Plough Ltd Canine lyme disease vaccine
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
EP2167536A1 (fr) 2007-07-03 2010-03-31 Dako Denmark A/S Procedes ameliores pour produire, marquer et utiliser des multimeres du cmh
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
CA2781110C (fr) * 2009-11-17 2018-07-31 Abaxis, Inc. Peptides et procedes pour la detection d'anticorps contre la maladie de lyme
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US9610336B1 (en) * 2014-07-16 2017-04-04 Amiram Katz Immunotherapy for lyme disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4772464A (en) 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
WO1991009870A1 (fr) * 1989-12-22 1991-07-11 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteines immunologiquement actives de borrelia burgdorferi, coffrets d'analyse connexes et vaccins
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ATE196425T1 (de) * 1990-07-06 2000-10-15 American Home Prod Impfstoff gegen die lyme-krankheit
CA2057536C (fr) * 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia
EP0877085A1 (fr) * 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. Protéines OspA des sous-groupes borrelia burgdorferi, gènes codants et vaccins
WO1993004157A1 (fr) * 1991-08-27 1993-03-04 Novo Nordisk A/S Compositions pour detergents
WO1993008299A1 (fr) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation de proteines borrelia recombinees
WO1993007897A1 (fr) * 1991-10-21 1993-04-29 Medimmune, Inc. Vecteurs d'expression bacteriens contenant de l'adn codant des signaux de secretion de lipoproteines

Also Published As

Publication number Publication date
CZ284616B6 (cs) 1999-01-13
PT95349A (pt) 1991-05-22
JP3418171B2 (ja) 2003-06-16
IE903377A1 (en) 1991-04-10
GR3018995T3 (en) 1996-05-31
EP0633028B1 (fr) 1999-11-17
NO20014624L (no) 1991-03-20
NO904062L (no) 1991-03-20
EP0643974A1 (fr) 1995-03-22
EP0633313A1 (fr) 1995-01-11
GR3032010T3 (en) 2000-03-31
FI102248B (fi) 1998-11-13
SK283088B6 (sk) 2003-02-04
ATE186646T1 (de) 1999-12-15
CZ97095A3 (en) 1995-09-13
NZ235260A (en) 1993-04-28
JP3205932B2 (ja) 2001-09-04
US6613331B1 (en) 2003-09-02
HU212716B (en) 1996-10-28
NO315905B1 (no) 2003-11-10
KR100202128B1 (en) 1999-06-15
SK151098A3 (en) 1999-04-13
DK0643974T3 (da) 1999-09-06
HU211228A9 (en) 1995-11-28
NO20014624D0 (no) 2001-09-24
CZ284538B6 (cs) 1998-12-16
DE59010863D1 (de) 1999-02-25
HK1002405A1 (en) 1998-08-21
YU49370B (sh) 2005-09-19
ATE191499T1 (de) 2000-04-15
SI9011773A (sl) 1998-04-30
GR3033675T3 (en) 2000-10-31
ES2145077T3 (es) 2000-07-01
NO904062D0 (no) 1990-09-18
DK0633028T3 (da) 2000-04-10
EP0633028A1 (fr) 1995-01-11
JPH03209400A (ja) 1991-09-12
DE59009978D1 (de) 1996-02-01
HK1013620A1 (en) 1999-09-03
HRP940545A2 (en) 1997-04-30
EP0643974B1 (fr) 1999-01-13
SK283089B6 (sk) 2003-02-04
SK151198A3 (en) 1999-04-13
SI9011773B (en) 2001-12-31
EP0861664A3 (fr) 1999-02-24
DK0418827T3 (da) 1996-05-06
ES2082812T3 (es) 1996-04-01
ES2141182T3 (es) 2000-03-16
EP0861664A2 (fr) 1998-09-02
AU651560B2 (en) 1994-07-28
DK0633313T3 (da) 2000-07-24
JP3328644B2 (ja) 2002-09-30
YU9097A (sh) 1999-06-15
EP0633313B1 (fr) 2000-04-05
FI904597A0 (fi) 1990-09-18
US5856447A (en) 1999-01-05
PT95349B (pt) 1997-06-30
SK280285B6 (sk) 1999-11-08
EP0418827A1 (fr) 1991-03-27
IE990173A1 (en) 2000-11-01
PL169804B1 (pl) 1996-09-30
US5686267A (en) 1997-11-11
JP2001069969A (ja) 2001-03-21
EP0418827B1 (fr) 1995-12-20
DE4015911A1 (de) 1991-03-28
JP2001204467A (ja) 2001-07-31
KR910005889A (ko) 1991-04-27
US5780030A (en) 1998-07-14
NO311767B1 (no) 2002-01-21
AU6244490A (en) 1991-03-28
CA2025597C (fr) 2004-02-03
CA2025597A1 (fr) 1991-03-20
ES2129551T3 (es) 1999-06-16
KR100205462B1 (ko) 1999-07-01
SK456090A3 (en) 1999-11-08
FI102248B1 (fi) 1998-11-13
HU905816D0 (en) 1991-03-28
DE59010903D1 (de) 2000-05-11
DE59010888D1 (de) 1999-12-23
ATE131732T1 (de) 1996-01-15
YU48250B (sh) 1997-09-30
US5434077A (en) 1995-07-18
CZ456090A3 (cs) 1998-08-12
HUT59613A (en) 1992-06-29
YU177390A (sh) 1993-05-28
PL170229B1 (pl) 1996-11-29
ATE175576T1 (de) 1999-01-15
US5178859A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
KR100202128B1 (en) Vaccine against lyme disease
AU8635391A (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
PT721506E (pt) Proteinas exportadas bacterianas e vacinas acelulares baseadas nestas
PT100781A (pt) Sequencias de dna codificadoras de proteinas de superficie externa, proteinas contendo as referidas sequencias, obtidas a partir de borrelia burgdorferi, e vacinas contendo as referidas proteinas
PL303482A1 (en) Vaccine against infection with streptococcus suis, streptococcus suis polypeptide and method of preparing such vaccine
AU6995291A (en) Recombinant coccidiosis vaccines -5-7 eimeria surface antigen
AU6860294A (en) New chondrocyte proteins
JPS6456695A (en) Peptide

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040727

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20050919